Methods for diagnosing and treatment of conditions that alter phosphate transport in mammals
AssigneeCuraGen Corporation
InventorRichard Shimkets
Life of this patent
Estimating the term…
Abstract
The present invention describes novel methods for diagnosis and treatment of conditions that alter phosphate transport in mammals. The fibroblast growth factor proteins and nucleotides that may be useful as a therapeutic or in the diagnosis of such conditions are also described.
Claims25
A method of diagnosing a hypophosphatemic condition in a mammal, said method comprising (a) obtaining a biological sample from the mammal and (b) contacting the biological sample with a reagent which detects the presence or absence of a mutation in a nucleic acid encoding FGF20 wherein the presence of said mutation is an indication that the mammal is afflicted with the hypophosphatemic condition.
A method of diagnosing a hypophosphatemic condition in a mammal, said method comprising (a) obtaining a biological sample from said mammal and (b) contacting the biological sample with a reagent which detects the presence or absence of a mutant form of FGF20 polypeptide, wherein the presence of the mutant form of FGF20 polypeptide is an indication that the mammal is afflicted with the hypophosphatemic condition.
A method of diagnosing a hypophosphatemic condition in a mammal, said method comprising (a) obtaining a biological sample from the mammal and (b) contacting the biological sample with a reagent that detects the level of FGF20 polypeptide in the sample, wherein an elevated level of FGF20 polypeptide in the sample, relative to the level of FGF20 polypeptide in a sample obtained from a control mammal, is an indication that the mammal is afflicted with said hypophosphatemic condition.
A method of diagnosing osteomalacia in a patient, said method comprising (a) obtaining a biological sample from the patient and (b) detecting the expression or lack thereof of FGF20 in the sample, wherein the expression of FGF20 is indicative of osteomalacia.
A method of treating a hypophosphatemic condition in a mammal, said method comprising administering to a mammal afflicted with the disorder a therapeutically effective amount of a FGF20 inhibitor selected from the group consisting of an inhibitor which reduces the level of mRNA encoding FGF20 polypeptide in the mammal, an inhibitor which reduces the level of FGF20 polypeptide in the mammal, and an inhibitor of the biological activity of FGF20 in the mammal.
A method of treating a hyperphosphatemic condition in a mammal, said method comprising administering to a mammal afflicted with the disorder a therapeutically effective amount of an isolated nucleic acid encoding FGF20.
A method of treating a hyperphosphatemic condition in a mammal, said method comprising administering to a mammal afflicted with the disorder a therapeutically effective amount of an isolated FGF20 polypeptide.
A method of treating a hyperphosphatemic condition in a mammal, said method comprising administering to the mammal afflicted with, a therapeutically effective amount of a reagent that increases the level of FGF20 polypeptide in said mammal.
A method of treating a hyperphosphatemic condition in a mammal, said method comprising administering to a mammal afflicted with, a therapeutically effective amount of a population of cells comprising an isolated nucleic acid encoding FGF20.
A method of treating a condition involving deposition of calcium and phosphate in the arteries or soft tissues of a mammal, said method comprising administering to said mammal a therapeutically effective amount of FGF20 or a reagent that increases the level of FGF20 polypeptide.
Dependencies are inferred from the claim text.